ArticleBMC rheumatology2026
Depressive symptoms are associated with achieving remission in PsA patients - an analysis from the RABBIT-SpA register.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepressive symptoms are common in psoriatic arthritis (PsA) and may influence treatment response. This study examined their association with achieving remission after starting a new systemic antirheumatic therapy, and tested whether this association differs by sex.
methodsData from PsA patients in the ongoing prospective longitudinal observational cohort study RABBIT-SpA were analyzed. Depressive symptoms were assessed with the WHO-5 Well-Being Index (none/mild vs. moderate/severe). Outcomes included minimal disease activity (MDA) and Disease Activity in Psoriatic Arthritis (DAPSA) remission at 3 and 6 months. Logistic regression assessed the association between baseline well-being and remission, adjusted for confounders identified using directed acyclic graphs. A sex × well-being interaction term was included in each model to test whether this association differs by sex. Multiple imputation handled missing data.
resultsModerate/severe depressive symptoms were present in 29% of 1,888 patients (34% of women, 23% of men). In adjusted analyses, higher baseline well-being was associated with remission (OR per 10-point increase: 1.06-1.14 across outcomes and timepoints, reaching significance for MDA at 6 months and DAPSA remission at both timepoints). Interaction testing showed no evidence that this association differed by sex; all four 95% confidence intervals included 1 (p ≥ 0.29). Both sexes with moderate/severe symptoms achieved MDA and DAPSA remission less frequently than those with no/mild symptoms. Although disease activity improved in both groups over time, it remained higher in patients with moderate/severe symptoms.
conclusionsDepressive symptoms were associated with higher disease activity and less frequent remission in PsA, with no evidence that this effect differed by sex. Routine screening for depressive symptoms should be considered in PsA management to identify patients at risk of suboptimal treatment response. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.